Leerink Partners cuts Henry Schein target price to $92 from $96
HSIC•Leerink Partners cut its target price for Henry Schein to $92 from $96.
Related News
Sanofi selects Recursion immunology drug candidate for development
SNY•
Niagen Bioscience schedules third-quarter financial results release
NAGE•
Lumen, Snowflake plan collaboration to simplify private data connectivity
SNOW•
Alpha Modus signs deal to test AI platform at three Greer's Markets stores
AMOD•
Tenon Medical secures eight new US patents through Q3 2026
TNON•